---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055652"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:38:53.075072+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alector Q1 net loss $36.1M ($0.38/share); cash runway through 2026

## Summary
- Q1 net loss $36.1M ($0.38/share) vs $45.9M ($0.55) in Q1 2023.
- Collaboration revenue $15.9M, roughly flat vs $16.5M year ago.
- Cash, equivalents & investments $562.1M; expects runway through 2026.
- INVOKE-2 Phase 2 TREM2 data for early Alzheimer's expected Q4 2024; INFRONT-3 Phase 3 latozinemab fully enrolled.
- Neil Berkley named CBO; Errol De Souza and Mark Altmeyer join Board.

## SEC filing metadata
- accession: 0000950170-24-055652
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017024055652/0000950170-24-055652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017024055652/alec-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055652
- JSON: https://secwatch.observer/filing/0000950170-24-055652.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055652.txt

## Key facts
- Earnings Releases
  Alector, Inc. reported financial results for First Quarter 2024.
  - Period: First Quarter 2024
  - Result: reported results
  source text: Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1653087/000095017024055652/0000950170-24-055652-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.